# Agios Pharmaceuticals, Inc.: Observational study closed enrollment, 500 enrolled (Pyruvate Kinase Deficiency)

**Score:** 85/100

| Field | Value |
|---|---|
| Sponsor | Agios Pharmaceuticals, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Pyruvate Kinase Deficiency Global Longitudinal Registry |
| NCT ID | NCT03481738 |
| Phase | Observational |
| Status | active not recruiting |
| Conditions | Pyruvate Kinase Deficiency |
| Target enrollment | 500 |
| Site countries | United States, Canada, Czechia, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, South Korea, Spain |
| Posted | 2018-03-29 |
| Planned start | 2018-04-23 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-28 |
| Last update posted | 2026-10-28 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- 500 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT03481738). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.